Empowered by global genetic expertise

As one of the most diversified and largest genetic testing companies worldwide we are dedicated to transforming the science of genetic information into solutions and hope for patients and their families.

Our goal is the rapid medical diagnosis of inherited diseases, provided at the earliest possible moment as we turn analytical information into actionable results for physicians, patients and pharmaceutical partners.

Our commitment to the global medical community is an early and precise diagnosis for continuous improvement of therapeutic options for each individual patient.

Our Latest Scientific News

  • Novel GNB1 mutations disrupt assembly and function of G protein heterotrimers and cause global developmental delay in humans

    Global developmental delay (GDD), often accompanied by intellectual disability, seizures and other features is a severe, clinically and genetically highly heterogeneous childhood-onset disorder. In cases where genetic causes have been identified, de-novo mutations in neuronally expressed genes are a common scenario. These mutations can be best identified by exome sequencing of parent-offspring trios. De novo mutations in the guanine nucleotide-binding protein, beta 1 (GNB1) gene, encoding the Gβ1 subunit of heterotrimeric G proteins, have recently been identified as a novel genetic cause of GDD.

  • Clinical exome sequencing - Results from 2819 samples reflecting 1000 families

    A study was conducted using whole exome sequencing (WES) to identify underlying pathogenic variants, or likely pathogenic variants, in 1,000 diagnostic cases from 54 different countries. Patients selected displayed a wide variety in the number, nature and severity of symptoms. Clinical information given by the requesting physicians was translated to HPO terms and WES was performed on patient samples according to standardized settings.

  • A comprehensive global genotype–phenotype database for rare diseases

    "The ability to discover genetic variants in a patient runs far ahead of the ability to interpret them. Databases with accurate descriptions of the causal relationship between the variants and the phenotype are valuable since these are critical tools in clinical genetic diagnostics. Here, we introduce a comprehensive and global genotype–phenotype database focusing on rare diseases."

CentoWebinar - A race against the clock - Diagnosing genetic conditions in newborns and children

Join our webinar on January 31, 2017; 4pm - 5pm CET.

Register now

Find the missing pieces of information

Start exploring the world’s largest clinically annotated, CE-labeled mutation database of rare diseases - CentoMD®.

Subscribe for a 14-day free trial

Subscribe to our Newsletter

CENTOGENE has recently added numerous single gene tests and next generation sequencing (NGS) panels to its portfolio. Our NGS panel compositions always reflect...

Read more

Dr. Arndt Rolfs, CEO CENTOGENE, presented at JP Morgan Healthcare Conference 2017 about CENTOGENE's self-amplifying business model - diagnostics, proprietary...

Read more

For the first time, ever, the Parkinson’s Institute and Clinical Center and CENTOGENE have entered into a collaboration aimed at genetic screening of a large...

Read more

Arndt Rolfs, CEO and founder of CENTOGENE, will present the company’s business model on Wednesday, January 11, 2017, at 4:30 pm PST.

Read more

CENTOGENE announces today a new sequencing facility for rare hereditary disorders, which will use Illumina’s HiSeq X® sequencer.

Read more

The “Deutschlandstipendium” is a scholarship that helps support gifted and talented students enrolled at German universities that are public institutions or are...

Read more

CENTOGENE is proud to contribute to the Face2Gene 60 Day Challenge. This initiative by FDNA was started November 1, 2016.

Read more

CENTOGENE successfully became part of the Illumina Propel Certification Program for Core and Service Labs.

Read more

CENTOEGENE AG (CENTOGENE) and Interactive Biosoftware (IBS) announce to start their collaboration on the integration of CENTOGENE’s unique genomic database...

Read more